Mesenteric panniculitis is a condition in which the fatty tissue of the mesentery, the fan-shaped fold that anchors your intestines to your abdominal wall, becomes chronically inflamed. It shows up on about 0.6% of abdominal CT scans, often as an incidental finding when imaging is done for an unrelated reason. Nearly half of people with mesenteric panniculitis have no symptoms at all, while others experience persistent abdominal pain, bloating, or digestive changes that can take time to diagnose.
How It Relates to Sclerosing Mesenteritis
Mesenteric panniculitis isn’t a standalone diagnosis so much as one stage within a broader process. Doctors use the umbrella term “sclerosing mesenteritis” to describe a spectrum of inflammation and scarring in the mesentery, and where you fall on that spectrum depends on what’s happening at the tissue level.
In the earliest stage, called mesenteric lipodystrophy, immune cells called macrophages begin replacing normal mesenteric fat. Inflammation is minimal, symptoms are rare, and the outlook is generally good. The second stage is mesenteric panniculitis itself, where inflammation ramps up significantly. Immune cells flood the tissue, and this is when symptoms are most likely to appear. If the process continues unchecked, it can progress to a third stage, sometimes called retractile or sclerosing mesenteritis, where scar tissue (fibrosis) begins to dominate. At this point, the mesentery can stiffen and contract, potentially pulling on or compressing the intestines.
Not everyone moves through all three stages. Many people remain at an early phase indefinitely, and the condition is not considered precancerous.
What Causes It
The short answer is that no one knows for certain. The inflammation in mesenteric panniculitis is classified as idiopathic, meaning it appears to arise spontaneously without a clear trigger like infection, injury, or cancer. The leading theory is that it may be a type of autoimmune response, where the immune system mounts a chronic inflammatory reaction against the mesenteric fat for no apparent reason. People with mesenteric panniculitis often have a strong family history of autoimmune diseases, which supports this idea.
About 5% of cases have been reported following abdominal surgery, suggesting that physical trauma to the area can occasionally set the process in motion. But for the vast majority, no triggering event is identified.
Common Symptoms
Abdominal pain is by far the most frequent complaint, reported by 54% to 78% of people who develop symptoms. The pain is typically located in the center of the abdomen and can range from a dull ache to something more persistent and disruptive. Beyond pain, the symptom picture varies widely:
- Bloating or abdominal distention: 9% to 26% of patients
- Diarrhea: 19% to 25%
- Weight loss: about 23%
- Fever: about 26%
- Vomiting: about 18%
- Anorexia (loss of appetite): about 13%
- Constipation: about 10%
Importantly, 16% to 40% of people with CT findings consistent with mesenteric panniculitis report no symptoms whatsoever. For these individuals, the condition is discovered only because a scan was performed for another reason entirely.
How It’s Diagnosed
Most cases are identified on a CT scan of the abdomen. Radiologists look for a few characteristic patterns in the mesenteric fat. The most recognizable is the “misty mesentery” sign, a hazy, cloudy appearance in the fat surrounding the intestines that indicates inflammation. A second hallmark is the “fat halo” sign, where a thin ring of preserved normal fat surrounds the blood vessels and lymph nodes within the inflamed area. In more advanced cases, a thin bright border called a pseudocapsule can form around the affected zone, giving it an almost tumor-like appearance on the scan.
These imaging features are distinctive enough that a biopsy isn’t always needed. However, when the findings are ambiguous or there’s concern about an underlying cancer, doctors may take a tissue sample to confirm the diagnosis and rule out other conditions, particularly lymphoma, which can look similar on imaging.
Links to Cancer
One question that often comes up is whether mesenteric panniculitis signals an underlying malignancy. The relationship is nuanced. In one study of 148 patients with mesenteric panniculitis, about 26% had a cancer diagnosis. The most common were breast cancer (6.1%), lymphoma (5.4%), and colorectal cancer (4.1%). Among all patients with lymphoma in that study, 6.56% had mesenteric panniculitis, the highest rate of any cancer type.
The association also appears to differ by sex. In men, mesenteric panniculitis was more strongly linked to lymphoma. In women, the association was stronger with breast cancer and multiple myeloma. That said, mesenteric panniculitis itself is not precancerous. It doesn’t transform into cancer. The connection seems to be that the same immune dysfunction or inflammatory environment that triggers the condition may also be present in people who develop certain cancers. For most people, mesenteric panniculitis is a benign finding that requires no cancer workup beyond what’s routine.
Treatment Options
Because so many cases are asymptomatic, the most common approach is simply observation. If the condition was found incidentally and you feel fine, your doctor may recommend periodic check-ins without any treatment at all. Long-term follow-up imaging is generally not considered necessary.
When symptoms are bothersome, corticosteroids are the first-line treatment. A typical starting dose is tapered gradually over 8 to 12 weeks, with doctors checking for improvement within the first two weeks. If the inflammation responds well, the dose is slowly reduced. Many people improve significantly with this approach alone.
For cases that don’t respond to corticosteroids or that relapse when the medication is tapered, doctors have several second-line options. These include immune-modulating medications, colchicine (an anti-inflammatory often used for gout), and hormonal therapy with tamoxifen. The choice depends on symptom severity and how the condition has responded to earlier treatment.
Surgery is rarely needed. In the largest published series, fewer than 5% of patients required an operation. The primary indication is recurrent bowel obstruction, where scarring or inflammation has narrowed the intestine enough to block it. Surgical options in those cases include removing the affected segment of bowel or releasing adhesions (bands of scar tissue).
What to Expect Long Term
For most people, mesenteric panniculitis follows a mild, self-limiting course. Symptoms may come and go, and the condition often stabilizes or resolves without aggressive treatment. Recurrence is possible but uncommon. In clinical follow-up studies spanning one to six months, complications directly related to mesenteric panniculitis were not observed, though occasional flares requiring a repeat course of anti-inflammatory treatment have been reported.
The main source of anxiety for many patients is the initial uncertainty. Seeing a mass-like finding on a CT scan is understandably alarming, and the condition’s rarity means some doctors are less familiar with it. Once other diagnoses have been excluded and the characteristic imaging pattern is confirmed, the prognosis is reassuring. Mesenteric panniculitis is a chronic inflammatory condition, not a progressive or life-threatening one for the vast majority of people who have it.